Stockwinners Market Radar for April 27, 2021 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:10 EDT Rain Therapeutics holder buys 550K shares of common stock - In a regulatory filing, Rain Therapeutics disclosed that its holder Perceptive Advisers bought 550K shares of common stock on April 27th in a total transaction size of $9.35M.

19:49 EDT Marker Therapeutics to present mTAA-specific T cell manufacturing data - Marker Therapeutics announced that it will present data detailing a new robotics technology to aid in multi-tumor-associated antigen (mTAA)-specific T cell therapy manufacturing at the upcoming American Society of Gene & Cell Therapy Annual Meeting, taking place virtually May 11-14, 2021. The data will be presented by lead author Anastasiya Smith, Ph.D. The presentation details how the robotic assistant prototype, co-designed by Marker Therapeutics and ABB Robotics, could in the future be integrated in a standard biosafety cabinet to collaborate with a human operator during mTAA-specific T cell manufacturing. The researchers found that the robotic assistant prototype was more precise and accurate than human operators in pipetting liquid and was more consistent in the number of cycles performed over a 1-hour test period, while the human operator's performance deteriorated over time. The authors conclude that the future combination of process simplification with robotic automation may be able to address some of the challenges associated with cell therapy and make this therapy readily available to a larger patient population.

18:56 EDT Bunge changes segment reporting to align with value chain operating structure - Bunge Limited announced that it has changed its segment reporting to align with the company's new value chain operating structure. Beginning with the first quarter 2021, Bunge will report Core Segment results as follows: Agribusiness, which includes processing and merchandising; Refined and Specialty Oils; and Milling. Bunge will also continue to report Corporate and Other results and Non-core Segment results, which is made up of Sugar & Bioenergy. The primary changes are elimination of the fertilizer reporting segment, the results of which are now included in the processing component of the Agribusiness reporting segment, the realignment of grains and oilseeds operations into processing and merchandising, as well as other immaterial reclassifications between Core and Corporate and Other segments. The segment reporting changes reflect a corresponding change in how the company's CEO reviews financial information in order to allocate resources and assess performance. In conjunction with this change, certain prior year amounts have been recast to conform to the new segment reporting structure. These changes have no impact on previously-reported consolidated balance sheets, statements of income (loss), comprehensive income (loss), changes in equity or cash flows.

18:36 EDT FDA AdCom in favor of maintaining accelerated approval for Genentech's Tecentriq - Genentech, a member of the Roche Group, announced the FDA Oncologic Drugs Advisory Committee voted 7 to 2 in favor of maintaining accelerated approval of Tecentriq in combination with chemotherapy for the treatment of adults with unresectable locally advanced or metastatic triple-negative breast cancer whose tumors express PD-L1, as determined by an FDA-approved test. Today's ODAC meeting is part of an industry-wide review of accelerated approvals with confirmatory trials that have not met their primary endpoint(s) and have yet to gain regular approvals. The advisory committee provides the FDA with independent opinions and recommendations from outside medical experts, though the recommendations are not binding. The FDA has not announced when it will make its final decision for Tecentriq in this indication. The FDA's Accelerated Approval Program allows for conditional approval of a medicine that fills an unmet medical need for a serious condition, with specific postmarketing requirements to confirm the clinical benefit and convert to regular approval.

18:25 EDT Omnicom CEO sells 81K shares of common stock - In a regulatory filing, Omnicom disclosed that its CEO John Wren sold 81K shares of common stock on April 26th in a total transaction size of $6.54M, reducing his stake by about 6%.

18:18 EDT Chipotle director buys 673 shares of common stock - In a regulatory filing, Chipotle director Matt Carey disclose a purchase of 673 shares of Chipotle stock on April 23rd in a total transaction size of $999.4K.

17:56 EDT Paccar increases quarterly dividend 6% - Paccar's board approved an increase of 6% in the regular quarterly cash dividend to 34c per share from 32c per share. The dividend will be payable on June 2 to stockholders of record at the close of business on May 12.

17:39 EDT Danaher senior VP Lalor sells over 3,000 common shares - In a regulatory filing, Danaher senior VP of Human Resources Angela Lalor disclosed the sale of 3,092 common shares of the company on April 23 at a price of $255.79 per share.

17:34 EDT Boeing awarded $106.82M Air Force contract modification - Boeing has been awarded a $106.82M change-order-definitization, cost-plus-incentive-fee modification to a contract for the Flight Test Telemetry Termination Rapid Fielding Initiative, or FT3 RFI. This contract allows the implementation of initiatives to meet the FT3 flight schedule. Work will be performed in Layton, Utah, and is expected to be completed June 28, 2024. No funds are being obligated at the time of award. Air Force Nuclear Weapons Center is the contracting activity.

17:32 EDT Takeda's Mobocertinib or TAK-788 granted FDA priority review in NSCLC treatment - Takeda Pharmaceutical announced that the FDA has granted priority review for the company's New Drug Application for mobocertinib,or TAK-788, for the treatment of adult patients with epidermal growth factor receptor Exon20 insertion mutation-positive metastatic non-small cell lung cancer, as detected by an FDA-approved test, who have received prior platinum-based chemotherapy. Mobocertinib is the first oral therapy specifically designed to selectively target EGFR Exon20 insertion mutations. The NDA for mobocertinib is primarily based on results from the Phase 1/2 trial, which is evaluating the safety and efficacy of oral mobocertinib in patients with mNSCLC. The application was submitted under the FDA's accelerated approval program.

17:28 EDT Lockheed Martin awarded $214.71M Army contract modification - Lockheed Martin was awarded a $214.71M modification to a contract for the M270A2 Multiple Launch Rocket System. Work has an estimated completion date of September 30, 2024. FY21 missile procurement, Army funds in the amount of $214.71M were obligated at the time of the award. U.S. Army Contracting Command is the contracting activity.

17:20 EDT Starbucks says resurgent COVID restrictions in China hurt Q2 results - Says U.S. comp growth attributable to increased customization and all-time high food attach. Says Q2 results in U.S. "phenomenal." Says "particularly pleased" with ability to improve digital operations in China during pandemic.

17:18 EDT Genworth to replace Glu Mobile in S&P 600 at open on 5/3 - Electronic Arts (EA) is acquiring Glu Mobile (GLUU) in a deal expected to be completed soon pending final conditions.

17:16 EDT Calix jumps 7% to $48.00 after Q1, Q2 outlook tops estimates

17:05 EDT Teradyne CEO says test demand 'stronger than expected' - "Coming off a strong 2020, we continued to grow both our Test and Industrial Automation businesses resulting in first quarter revenue growth of 11% compared to one year ago," said Teradyne President and CEO Mark Jagiela. "Test demand for automotive, industrial, memory, and mobility remain strong and growing. The Industrial Automation recovery is in full swing with 33% growth compared to Q1 2020. Looking ahead, test demand at this point in the year is stronger than expected fueled by both continued device complexity increases and unit growth. Both the SOC and Memory test markets will likely exceed the top end of our market forecast resulting in higher sales and profits as reflected in our Q2 guidance. Additionally, increasing forecasts for wafer fabrication equipment investments are a strong indicator for test growth in the years to come. In Industrial Automation, we remain on track for more than 30% revenue growth in 2021 as demand continues to strengthen."

17:02 EDT Oceaneering wins multiple contracts with anticipated aggerate revenue of $135M - Oceaneering announced that its manufactured products segment has won multiple contracts during the first four months of 2021, with anticipated aggregate revenue in excess of $135M. The anticipated revenue from these contracts with international oil and gas operators and marine construction companies ranges in value from less than $10M to greater than $90M. Each contract scope of work involves the manufacture of subsea production umbilicals and umbilical termination hardware at one of Oceaneering's facilities, located in Panama City, Florida, Niteroi, Brazil, and Rosyth, Scotland. Manufacturing of the umbilicals is expected to commence promptly, with production schedules ranging in duration from several months to five years.

16:57 EDT Boston Properties: Roku signs new 10-year lease agreement in Santa Monica, CA - Boston Properties (BXP) announced that Roku (ROKU) has signed a new, 10-year lease agreement for 72,000 square feet in BXP's 1.2M square foot Colorado Center office campus in Santa Monica, California.

16:40 EDT Capital One CEO says investments to transform technology 'paying off' - "Strikingly strong credit drove another quarter of record earnings per share, and our investments to transform our technology and how we work are paying off," said Richard Fairbank, Founder, Chairman and CEO. "Our modern technology is powering our response to the pandemic, and putting us in a strong position for opportunities that emerge as sweeping digital change transforms banking."

16:36 EDT Amgen drops 5% to $242.90 after Q1 results miss estimates

16:35 EDT Humana to acquire remaining interest in Kindred at Home - Humana announced it has signed a definitive agreement to acquire the remaining 60% interest in Kindred at Home, or KAH, from TPG Capital, the private equity platform of global alternative asset firm TPG, and Welsh, Carson, Anderson & Stowe for an enterprise value of $8.1B, which includes Humana's existing equity value of $2.4B associated with its current 40% minority ownership interest. KAH employs approximately 43,000 caregivers providing home health, hospice and community care services to over 550,000 patients annually. KAH has locations in 40 states, providing extensive geographic coverage with approximately 65% overlap with Humana's individual Medicare Advantage membership. This acquisition, which is expected to close in the third quarter of 2021, is subject to customary state and federal regulatory approvals. Humana expects to fund the approximately $5.7B transaction through a combination of parent company cash and debt financing. The company does not anticipate a material impact to earnings in 2021 from this pending transaction. Humana expects the transaction to provide modest additional financial flexibility for 2022.

16:33 EDT Yum China backs FY21 CapEx view $600M - Expects to open approximately 1,000 new stores (gross).

16:31 EDT Idex Corp. to acquire Airtech for $470M - IDEX announced that it has entered into a definitive agreement to acquire Airtech Group, Inc., US Valve Corporation and related entities from investment funds managed by EagleTree Capital for cash consideration of $470M, subject to customary post-closing adjustments. The company provides customized solutions across diversified end markets such as alternative energy, food processing, medical, packaging and transportation. Airtech serves clients globally, with operations in the United States, Europe and Asia.

16:28 EDT Amgen sees FY21 CapEx $900M

16:26 EDT Ingevity announces strategic partnership with RNG platform GreenGasUSA - Ingevity announced a strategic partnership with and investment in GreenGasUSA Holdings, LLC, an integrated renewable natural gas solutions provider helping customers reduce their environmental impact. Charleston, South Carolina-based GreenGas contracts with agricultural farms, landfills and industrial and municipal wastewater treatment facilities to collect and treat biogas from the organic waste of their operations that it then sells as pipeline-quality, low-carbon RNG. GreenGas also provides compression, transportation and delivery of natural gas directly to customers through its wholly owned pipeline injection point or as part of its virtual pipeline services. With this investment, Ingevity now holds a less than 50% ownership in GreenGas. Initially, Ingevity's funding will enable GreenGas to further develop biogas capture and cleanup systems at facilities where harmful methane-producing organic waste can be converted to RNG instead of being flared off or escaping into the atmosphere. GreenGas founder Marc Fetten will continue as GreenGas CEO, overseeing growth strategy and business development efforts. Ingevity said it will now play an active role in exploring and accelerating the application of its activated carbon-based, low-pressure adsorbed natural gas technology for the storage and transport of natural gas as part of the GreenGas model. The collaboration will also be integral in facilitating RNG use within Ingevity's ANG vehicle platform by offering fleet customers broader access to the benefits of RNG as a transportation fuel, which Natural Gas Vehicles of America notes reduces greenhouse gas emissions by up to 125%. Looking to the future, Ingevity is uniquely positioned to leverage its expertise as an operating and technology partner for GreenGas, while the investment also helps Ingevity gain a foothold in the rapidly expanding RNG industry.

16:25 EDT Amgen reports Q1 total product sales down 5% - Total product sales decreased 5% for the first quarter of 2021 versus the first quarter of 2020. Unit volumes grew 4% while net selling price declined 7%. Year-over-year growth was negatively impacted by 2% due to a benefit in Q1 2020 from ~$150M of changes to estimated sales deductions that did not recur to the same magnitude in Q1 2021. In addition, in Q1 2021, Enbrel, Otezla and Aimovig followed the historic pattern of lower Q1 sales relative to the remainder of the year due to the impact of benefit plan changes, insurance reverifications and increased co-pay expenses as U.S. patients work through deductibles.

16:24 EDT Amgen CEO 'remains confident' in FY21 outlook - "While our business continued to be impacted by the COVID-19 pandemic particularly in the first two months of the quarter, we are encouraged by strong volume trends in many of our newer products and remain confident in the outlook for the full year," said Robert Bradway, chairman and CEO. "We also continue to advance key pipeline opportunities, including three late-stage assets that have earned Breakthrough Therapy Designation from the U.S. Food and Drug Administration."

16:23 EDT Provention Bio provides regulatory update on BLA for teplizumab - Provention Bio announced the company took part in an informal meeting with the U.S. FDA on April 23 in connection with the FDA's ongoing review of the teplizumab Biologic License Application for the delay or prevention of clinical type 1 diabetes. The purpose of this meeting was to discuss the FDA's considerations, thus far, regarding comparability between the Company's proposed commercial product and drug product used historically in clinical trials originating from drug substance manufactured by Eli Lilly over a decade ago. The FDA reported at the meeting that it had concluded that the pharmacokinetic (PK) profiles of the two drug products evaluated in the Company's single, low-dose pharmacokinetic/pharmacodynamic bridging study conducted in healthy volunteers are not comparable, since the intended commercial product did not meet the pre-specified 80-125% PK area under the curve comparability target range. The FDA also stated that it cannot be certain if this observation is not clinically relevant, given that the relationship between transient lymphocyte reduction, a PD marker, which was comparable in the PK/PD bridging study, and clinical efficacy, has yet to be fully validated. The FDA emphasized its understanding of the high unmet need associated with delaying the onset of clinical-stage T1D and reiterated their willingness to work with the Company to find a solution and path forward for the comparability issue. Nevertheless, the Company is reiterating previous guidance that the FDA's PK comparability considerations are likely to result in a delay in potential BLA approval timelines and that the specifics of such delay will depend upon the outcome of ongoing discussions with the FDA to find a solution, including potentially providing FDA reviewers with PK/PD data from the Company's on-going Phase 3 PROTECT study in newly diagnosed patients. The FDA also informed the Company that it plans to mention its PK comparability review in the clinical pharmacology summary of its briefing materials for the Advisory Committee meeting on May 27th, along with a statement that the FDA is actively working with the Company to resolve the issue and that the focus of the Advisory Committee meeting is efficacy and safety of teplizumab. It is the Company's understanding that since the FDA's PK comparability considerations do not bear on the benefit-risk assessment of the TN-10 study clinical data package, no comparability related questions or discussion topics are planned for the meeting. The FDA also recommended that both the FDA and the Company update their Advisory Committee briefing materials to reflect the removal of the term "prevention" from the previously proposed indication, as the remaining term "delay" more accurately reflects the results of the TN-10 trial. "We would like to thank the FDA for meeting with us to explain its PK comparability considerations, thus far, and especially for its willingness to work with us to find a path forward," stated Ashleigh Palmer, CEO and Co-Founder, Provention Bio. "We are also fully aligned with the FDA's recommendation to remove the term 'prevention' from the wording of teplizumab's initial indication and instead focus exclusively on delaying the progression of disease. We believe this will help to reinforce the fact that, while pre-symptomatic, T1D patients with two autoantibodies and dysglycemia already have the disease and may benefit from therapeutic options targeting the preservation of functional beta cell mass. We remain enthusiastic about the clinical efficacy and safety data submitted in connection with the BLA in support of teplizumab's potential to address the high unmet needs of pre-symptomatic T1D patients. Finally, we are looking forward to participating alongside the patient community, treating physicians, and additional members of the T1D community in the upcoming FDA Advisory Committee Meeting, the importance of which could not be more clear at this juncture."

16:20 EDT MetLife raises quarterly dividend by 4.3% to 48c per share - The dividend will be payable on June 14, 2021, to shareholders of record as of May 11, 2021.

16:18 EDT Juniper sees sufficient semi supply to meet full-year forecast - Juniper said, "We have invested to strengthen our supply chain and have increased inventory levels over the course of the last year. We continue to work closely with our suppliers to further enhance our resiliency and mitigate recent disruptions outside of our control. Despite these actions, we believe extended lead times will likely persist for the next few quarters. While the situation is dynamic, at this point in time, we believe we will have access to sufficient semiconductor supply to meet our full-year financial forecast."

16:16 EDT PPD not providing guidance - The company states: "Due to the proposed merger with Thermo Fisher previously announced on April 15, 2021, which is subject to regulatory approvals in addition to the satisfaction of customary closing conditions, PPD will no longer be providing financial guidance."

16:12 EDT NCR Corp. expects Covid-19 pandemic to negatively impact business - The company said: "While it is difficult to project how disruptive and protracted the pandemic will be, we do expect it will negatively impact our business. We expect all of our segment results to be negatively impacted by the COVID-19 pandemic. We expect our hardware revenues to be most impacted while our recurring revenue streams are expected to be more resilient."

16:11 EDT Visa not providing FY21 outlook - "Given the continuing impact of COVID-19 and the significant uncertainty in the global economy, it is difficult to reasonably estimate the Company's annual results; therefore we are not providing a fiscal full-year 2021 outlook at this time," the company said.

16:10 EDT Alphabet Class A shares up 4% to $2,392.65 after Q1 earnings report

16:09 EDT Hawaiian Holdings sees Q2 total revenue down 45%-50% - Sees Q2 ASMs down 30%-33%; Operating Expenses, excluding non-recurring items down 20%-24%; Interest expense $30M; Adjusted EBITDAR ($70M)-($20M); effective tax rate ~21%; and Fuel Price per Gallon $1.75.

16:08 EDT Microsoft reports Q3 Commercial Cloud revenue $17.7B - Reports Productivity & Business Processes revenue $13.6B, Intelligent Cloud revenue $15.1B.

16:07 EDT Y-mAbs submits Omburtamab MAA to European Medicines Agency - Y-mAbs Therapeutics announced that the Company has submitted its Marketing Authorization Application to the European Medicines Agency for omburtamab for the treatment of pediatric patients with CNS/leptomeningeal metastasis from neuroblastoma. Omburtamab is an investigational, monoclonal antibody that targets B7-H3 and is radiolabeled before intraventricular central nervous system administration. B7-H3 is an immune checkpoint molecule that is widely expressed in tumor cells of several cancer types. "We believe omburtamab is on track to potentially become the first EMA approved targeted therapy for pediatric patients with CNS/leptomeningeal metastasis from neuroblastoma," said Thomas Gad, founder, Chairman and President at Y-mAbs. "With this submission to EMA, Y-mAbs is continuing to advance the omburtamab program to potentially provide access to this innovative therapy to pediatric patients globally as quickly as possible." In addition, Y-mAbs recently concluded a Type B meeting with the U.S. Food and Drug Administration regarding omburtamab and the Company continues to be in close dialog with the FDA and maintains its aim of resubmitting the Biologics License Application to the FDA late in the second quarter or in the third quarter of 2021. Dr. Claus Moller, the Company's Chief Executive Officer, continued, "We are excited to submit the MAA for omburtamab, and very pleased about the progress we are making. We believe omburtamab can potentially address a significant unmet medical need for children with CNS/leptomeningeal metastasis from neuroblastoma. We also are continuing to work closely with the FDA to resubmit the omburtamab BLA."

16:06 EDT Bloom Energy deploys first fuel cells powered solely by hydrogen - Bloom Energ announced that, in collaboration with its Korean partner, SK Engineering & Construction Co., Ltd., an affiliate of SK Group, it has successfully deployed 100 kilowatts of solid-oxide fuel cells powered solely by hydrogen in Ulsan, South Korea, generating zero-carbon onsite electricity.

16:05 EDT Alphabet reports Q1 Google Cloud revenue $4.05B vs. $2.78B a year ago

16:04 EDT Cubic receives shareholder approve of Veritas merger pact - Cubic Corporation announced that, at a special meeting of shareholders held on April 27, 2021, the shareholders of the company approved a proposal to adopt the merger agreement entered into between the Company and an affiliate of Veritas Capital, under which Veritas and Evergreen Coast Capital Corporation, an affiliate of Elliott Investment Management L.P., will acquire the company for $75.00 per share in cash. Approximately 70.3% of the shares of the company's common stock issued and outstanding as of the close of business on March 18, 2021, the record date for the Special Meeting, voted to adopt the Merger Agreement. The proposed transaction remains subject to the receipt of certain regulatory approvals and the satisfaction of other closing conditions. The Company currently anticipates that the proposed transaction will be completed during the second calendar quarter of 2021.

16:01 EDT Cyberoptics receives $2.4M Mini LED inspection/metrology order - CyberOptics announced that it has received a new order valued at approximately $2.4M for its SQ3000(TM) Multi-Function systems for mini LED inspection and metrology. The systems are expected to ship periodically through-out 2021, starting in the second quarter ending June 30.

15:46 EDT ServisFirst CFO Foshee sells 3,000 shares of company stock - ServisFirst CFO William Foshee disclosed n a filing that he had sold 3,000 shares of company stock at $63.81 per share on April 27, for a total transaction amount of $191,430.

15:01 EDT Norfolk Southern declares 99c per share dividend, accelerates payment date - Norfolk Southern announced a regular quarterly dividend of 99c per share on its common stock. The dividend is payable May 20 to shareholders of record on May 7. "Norfolk Southern is reducing the days between shareholder of record date and payable date beginning this quarter, effectively accelerating payments to shareholders," the company stated.

14:54 EDT Southern Copper calls Mexico vaccine efforts 'very positive development' - The company said, "We believe that the vaccination efforts, which have been carried out by the state of Sonora (Mexico), represent a very positive development. Through this endeavor, 100% of the medical personnel at our operations have been vaccinated. Similarly, 98% of the workers over the age of 60 in Cananea, and 100% of those in Nacozari, have also received a vaccine. This significant advance gives our personnel needed protection against the COVID-19 virus; provides peace of mind to both workers and their families; and allows the Company to begin normalizing operating levels at our installations. Our Company is contributing to this effort by providing logistical support during the vaccination roll-out."

14:31 EDT State Street names Aman Thind global chief architect - State Street announced that it has appointed Aman Thind to executive vice president and global chief architect. In this role Thind will report to Brian Franz, global chief information officer. "With experience on both the trading floor and in technology strategy, Aman brings a unique perspective to our technology roadmap across multiple dimensions," said Franz. "Technology will continue to be a key enabler of our clients' growth objectives and we are confident that Aman's expertise will enhance the delivery of solutions, help them accelerate time to market and build stability, resiliency and scalability into their operations."

14:17 EDT General Electric reports 400 LEAP-1B unit order cancellations recorded in Q1 - In a regulatory filing, GE disclosed that Aviation segment orders were down $2.0B, or 26%, segment revenues were down $1.9B, or 28%, and segment profit was down $0.4B, or 36%, for the three months ended March 31, 2021. "Backlog as of March 31, 2021 decreased $1.0B from December 31, 2020, primarily due to approximately 400 LEAP-1B unit order cancellations. Backlog decreased $13.9B - 5% - from March 31, 2020, primarily due to a reduction in our Commercial Services backlog and cancellations of commercial equipment orders, which included approximately 1,900 LEAP-1B unit order cancellations," the company's 10-Q filing stated.

13:02 EDT CynergisTek announces expansion renewal of $1.4M managed services agreement - CynergisTek announced a $600,000 managed services renewal agreement with a long-term client along with over $800,000 in new services to add coverage for its new affiliate hospitals to conduct on-going security risk assessments and related services.

12:44 EDT SVB Financial confirms purchase price for Boston Private is 'best and final' - On April 27, 2021 Boston Private Financial Holdings (BPFH) adjourned its special meeting of shareholders until May 4, 2021 to solicit additional votes in support of the merger between Boston Private and SVB Financial Group (SIVB). To provide clarity to Boston Private shareholders, SVB is confirming it will not increase the purchase price if Boston Private shareholders do not approve the transaction at the adjourned meeting.

12:29 EDT Liquid Media announces Andy Wilson replaces Daniel Cruz as CFO - Liquid Media Group announces that Andy Wilson has joined Liquid as the chief financial officer of the company. Wilson will replace the company's prior CFO, Daniel Cruz. "Cruz will remain involved with the company both in his capacity as a director, as well as in a Senior Advisor role," Liquid Media said.

12:05 EDT Ford announces Ford Ion Park global battery center of excellence - Ford today announces a new global battery center of excellence - called Ford Ion Park - to accelerate research and development of battery and battery cell technology - including future battery manufacturing. The company is building on nearly two decades of battery expertise by centralizing a cross-functional team of 150 experts in battery technology development, research, manufacturing, planning, purchasing, quality and finance to help Ford more quickly develop and manufacture battery cells and batteries. The Ford Ion Park team also is exploring better integration and innovation opportunities across all aspects of the value chain - from mines to recycling - working with all teams within Ford, including experts at Ford's new Battery Benchmarking and Test Laboratory, Ford Customer Service Division, plus key suppliers and partners. The Ford Ion Park team already is underway. In addition, a $185 million collaborative learning lab in Southeast Michigan that is dedicated to developing, testing and building vehicle battery cells and cell arrays opens late next year. This world-class 200,000 sq.-ft. learning lab will include pilot-scale equipment for electrode, cell and array design and manufacturing and will use state-of-the-art technology to pilot new manufacturing techniques that will allow Ford to quickly scale breakthrough battery cell designs with novel materials once the company vertically integrates battery cells and batteries. Anand Sankaran will lead the Ford Ion Park team as its new director. A 30-year veteran of Ford, Sankaran brings to the new position decades of battery and electrification expertise - including his current role as the company's director of Electrified Systems Engineering, as a 1999 Henry Ford Technology Award winner for his electrification work at the Ford Research Lab and a product development leader who applied his research and technical innovations on key production vehicles, including the award-winning original Escape Hybrid, 2021 Mustang Mach-E and 2022 F-150 Hybrid.

12:02 EDT TriNet falls -7.3% - TriNet is down -7.3%, or -$6.15 to $78.15.

12:01 EDT PQ Group falls -13.5% - PQ Group is down -13.5%, or -$2.26 to $14.44.

12:00 EDT Aaron's rises 20.4% - Aaron's is up 20.4%, or $5.38 to $31.82.

11:42 EDT Sorrento Therapeutics gets FDA clearance to proceed with Phase 2 Sti-3031 study - Sorrento Therapeutics and its development partners have advanced into clinical development a number of fully human monoclonal antibodies or the treatment of COVID-19 and various cancers. Two independent anti-PD-L1 mAbs are now in Phase 2 and Phase 3 clinical studies. A PD-L1 mAb was licensed to ImmuneOncia Therapeutics, a joint venture between Sorrento and Seoul-based Yuhan Corporation. IMC-001 has completed a Phase 1b study in patients with metastatic or locally-advanced solid tumors and is nearing completion of a Phase 2, open-label, "Neo-Chance" study in patients with resectable gastric cancer, esophageal cancer and liver cancer. ImmuneOncia has also started to enroll patients in a Phase 2 study in relapsed or refractory extranodal NK/T cell lymphoma, nasal type. Sorrento has filed an IND in the U.S. and received clearance from the FDA to proceed with a Phase 2a study for STI-3031 for advanced urothelial carcinoma. A second antibody, Socazolimab, is licensed to Lee's Pharmaceutical Holdings Limited in the Greater China territory, and has been cleared to begin a multicenter Phase 3 trial as a potential first-line treatment for patients with extensive-stage small-cell lung cancer. Professor Shun Lu is the Principal Investigator. Additionally, Phase 1b studies in several other indications have been completed for this product candidate, including: recurrent metastatic cervical cancer, advanced urothelial carcinoma, and high-grade osteosarcoma after adjuvant chemotherapy for maintenance. In addition, a Phase 1b/2 study has been initiated as a potential neoadjuvant treatment option for esophageal carcinoma. For cervical cancer, a pivotal study has been completed with a breakthrough therapy designation granted by the National Medical Products Administration in China. Sorrento intends to open an IND in the U.S. with the intent to have an end-of-phase 3 meeting or pre-NDA discussion with the FDA for various cancer indications.

11:11 EDT Turner Sports, NHL announce seven-year multimedia rights agreement - Earlier, Turner Sports, a division of WarnerMedia, and the National Hockey League announced they have reached a "multi-faceted," seven-year agreement set to begin with the 2021-22 season. "This historic multimedia rights agreement will bring the Stanley Cup Final and Stanley Cup Playoffs to TNT and TBS for the first time, along with providing Turner Sports rights to up to 72 regular season games and the NHL Winter Classic each season. The multi-year agreement is highlighted by TNT crowning a champion through its exclusive live coverage of the Stanley Cup Final in three of the seven years; half of the Stanley Cup Playoffs each year; and rights to up to 72 exclusive national regular season games each season. Additionally, TNT will exclusively present the NHL Winter Classic each year, among other live events. Live game and studio coverage details, along with programming plans, will be announced in the months ahead," Turner Sports stated. Reference Link

10:43 EDT Polaris sees Q2-Q4 'very similar' to Q1 in terms of revenue, profitability - Comments taken from Q1 earnings conference call.

10:20 EDT JetBlue 'pleased' with demand returning so quickly

10:17 EDT JetBlue sees achieving better than 2019 CASM ex-fuel in 2022

10:17 EDT JetBlue sees Q2 EBITDA ($200M)-($100M), reflecting acceleration of demand

10:15 EDT JetBlue sees unit revenue improving meaningfully in Q2

10:09 EDT Canadian Pacific sends letter to Surface Transportation Board - Canadian Pacific Railway Limited (CP) filed a letter with the Surface Transportation Board. The letter says in part: "I am writing on behalf of the Canadian Pacific Applicants in Finance Docket No. 36500,1 in response to the letter submitted by Canadian National (CNI) on April 26 in the above-referenced dockets. In that submission, CN asks the Board to subject the voting trust arrangement proposed by Canadian Pacific for its acquisition of Kansas City Southern (KSU) to the same review process and standards that govern CN's proposed voting trust. CN's position is both contrary to law and fundamentally at odds with the very different factual contexts of the two voting trust proposals. Accordingly, we respectfully submit that the Board should proceed to review each of the pending voting trust proposals under the different regulatory review processes and standards applicable to each of them. CN's proposal, by its own admission, is subject to the 2001 rules and their requirement that the Board conduct the "public interest" review mandated by new Section 1180.4(b)(4), which goes beyond consideration of whether the trust will insulate KCS from premature control.2 The Board should proceed to establish a process for consideration of CN's proposal, in which CP intends to participate. Though CP will in due course demonstrate why approval of CN's proposal to acquire the shares of KCS prior to obtaining control authorization is not in the public interest, CP wishes to expand briefly on why there is no merit to CN's suggestion that its trust proposal should be subject to the same review process as CP's proposal... CP requests that the Board proceed with each of the pending voting trust proposals under the different regulatory review processes and standards that apply to them. CP appreciates the Board's attention to this matter."

10:08 EDT JetBlue sees ongoing demand acceleration continuing into summer - Comments taken from Q1 earnings conference call.

10:02 EDT CPSI names Amaris McComas as new Chief People Officer - CPSI (CPSI) announced that Amaris McComas has been named the company's new Chief People Officer, effective May 3. In this new senior role for CPSI, McComas will have oversight of all of the company's organizational and leadership development, talent management, succession planning, compensation, and benefits for the approximately 2,000 CPSI employees, including an expanding remote workforce. McComas brings over 15 years of experience in human resources management to CPSI and most recently served as Head of Talent, Strategy and Transformation for Equitable (EQH).

10:01 EDT Medtronic receive breakthrough designation for Emprint ablation catheter kit - Medtronic announced it has received Breakthrough Device Designation status from the U.S. Food and Drug Administration for the Emprint ablation catheter kit - an investigational device not yet approved or cleared in the United States. The catheter is intended to be used in conjunction with the Emprint microwave generator and Medtronic lung navigation platform to provide a minimally invasive, localized treatment of malignant lesions in the lung, and it can be used together with standard of care therapy when indicated.

10:00 EDT Skillz falls -7.4% - Skillz is down -7.4%, or -$1.57 to $19.59.

10:00 EDT UPS rises 10.3% - UPS is up 10.3%, or $18.19 to $194.00.

10:00 EDT TrueBlue rises 20.7% - TrueBlue is up 20.7%, or $4.77 to $27.83.

09:50 EDT InspireMD trading resumes

09:47 EDT X Financial falls -6.0% - X Financial is down -6.0%, or -24c to $3.78.

09:47 EDT PQ Group falls -11.7% - PQ Group is down -11.7%, or -$1.96 to $14.74.

09:47 EDT TrueBlue rises 12.7% - TrueBlue is up 12.7%, or $2.93 to $25.99.

09:45 EDT InspireMD trading halted, volatility trading pause

09:34 EDT Nevada reports March statewide gaming win up 72.66% to $1.07B - Nevada reports March Las Vegas Strip gaming win up 67.21% to $501.46M versus last year's $299.89M. Publicly traded companies in the gambling space include Boyd Gaming (BYD), Caesars (CZR), Churchill Downs (CHDN), DraftKings (DKNG), Flutter Entertainment (PDYPY), Gan Limited (GAN), Las Vegas Sands (LVS), MGM Resorts (MGM), Penn National (PENN), William Hill (WIMHY) and Wynn Resorts (WYNN).

09:31 EDT Amazon announces new Fire HD 10 tablets - Amazon announced the next generation of Fire HD 10 tablets. The Fire HD 10 and first Fire HD 10 Plus offer a brighter full HD display, updated design, and new features. Plus, with the Fire HD 10 Productivity Bundle, customers can get more done with a detachable keyboard case and a Microsoft 365 Personal subscription. Amazon also introduced an all-new Fire HD 10 Kids tablet for kids ages three to seven, and new Fire Kids Pro tablets built with six to 12 year-olds in mind. "Our best tablets just keep getting better. The new Fire HD 10 is brighter, thinner, and lighter, with an octa-core processor for fast and responsive performance, 50% more RAM, and all-day battery life-and is still only $149.99," said Kevin Keith, vice president, Amazon Devices. "Plus, we added new apps, features, and accessories, including a Productivity Bundle with the Fire HD 10, a Microsoft 365 Personal subscription, and a detachable keyboard case, to help you get more done."

09:28 EDT CPI Aerostructures receives $4.4M purchase order from U.S. Air Force - CPI Aerostructures announced that it has been awarded a $4.4M purchase order under a previously announced contract from the U. S. Air Force to provide structural modification kits, program management, logistics, and other sustainment services in support of Phase 3 of the T-38C Pacer Classic III Fuselage Structural Modification Kit Integration program and the Talon Repair Inspection and Maintenance program. In July 2019, the company announced the PCIII and TRIM contract valued at up to $65.7M. The new purchase order brings the total funded value of the contract to $28.4M and extends the currently funded period of performance into late 2024. The Northrop T-38 has been the principal supersonic jet trainer used by the Air Force for more than 50 years. PCIII and TRIM are expected to increase the structural service life of the aircraft to beyond 2030.

09:26 EDT ClearOne reviews features of its products in relation to the pandemic - ClearOne shares the experiences of CelebExperts CEO Evan Morgenstein when using their products during the pandemic. "As a talent representative and booker whose job requires making great first impressions and providing responsive, reliable service to clients, Morgenstein has been able to rise above the challenges presented by Covid with the help of the ClearOne Aura Versa 50 videoconferencing system that offers 4K video clarity and superior audio capture and playback," the company said. " Morgenstein views his upgraded equipment as akin to his early adoption of the iPhone...The ClearOne Aura Versa 50 system is a massive upgrade from the integrated cameras and microphones found in laptops. The screen-mountable UNITE 50 4K ePTZ camera includes pan, tilt and 4x zoom functions controlled by a remote, while the CHAT 150 USB speakerphone provides crystal-clear HDConference audio quality with physical buttons for volume and mute functions," ClearOne added. "In addition to the 4K video quality upgrade, Morgenstein said the improved audio clarity on both sides of the conversation helps keep meetings on schedule, aids in understanding non-native English speakers and limits the need for people to repeat themselves. Essentially, the goal is to achieve the responsiveness and feel of an in-person meetings," the company stated.

09:26 EDT Cyclo announces design of study evaluating Trappsol Cyclo in Niemann-Pick - Cyclo Therapeutics announced that it has posted its protocol on www.ClinicalTrials.gov and is preparing to commence its pivotal Phase 3 study evaluating Trappsol Cyclo, a proprietary formulation of hydroxypropyl beta cyclodextrin, used intravenously, in the treatment of Niemann-Pick Disease type C. Both the FDA and EMA are in agreement with the Company's pivotal Phase 3 protocol and have given clearance to proceed with the study. NPC is a rare genetic disease affecting 1 in 100,000 live births globally. NPC affects every cell in the body due to a defect in the NPC1 protein which is responsible for cholesterol processing in the cell. As cholesterol accumulates in cells, NPC causes symptoms in the brain, liver, spleen,

09:23 EDT Osisko Development announces drilling results from Cariboo drill program - Osisko Development Corp. is pleased to announce drilling results from the category conversion drill program campaign at its Cariboo Gold Project in central British Columbia. This news release discusses the final assay results from the 2020 exploration and delineation drill campaign on Valley, Mosquito and Shaft Zones and includes holes CM-20-100 to CM-20-105 and IM-20-036 to IM-20-061. Detailed drilling results, drill hole location plan maps and vertical sections are presented at the end of this release. The infill drilling results continue to demonstrate continuity and expansion of modelled vein corridors. Drilling highlights include 6.97 g/t Au over 6.50 g/t Au and 7.73 g/t Au over 13.00 meters in hole CM-20-100. Hole CM-20-100 confirmed anomalous gold values within multiple modelled vein corridors. On Island Mountain, Shaft Zone highlights included 11.48 g/t Au over 8.35 meters in hole IM-20-039 and on Mosquito Creek Zone 22.76 g/t Au over 7.00 meters in hole IM-20-053. The modelled vein corridors remain open at depth and are currently being drill tested with four diamond drill rigs. A total of ten rigs are currently active on Cariboo. Recent Drilling Highlights: CM-20-100: 6.97 g/t Au over 6.50 meters; CM-20-100: 7.73 g/t Au over 13.00 meters including 35.50 g/t Au over 0.85 meter; CM-20-101: 30.70 g/t Au over 1.35 meters; CM-20-102: 5.62 g/t Au over 9.45 meters including 28.10 g/t Au over 0.50 meter; IM-20-037: 7.14 g/t Au over 5.05 meters; IM-20-037: 15.45 g/t Au over 4.50 meters including 56.20 g/t Au over 0.50 meter; IM-20-039: 17.84 g/t Au over 4.30 meters including 42.30 g/t Au over 1.25 meters; IM-20-039: 11.48 g/t Au over 8.35 meters including 66.50 g/t Au over 0.65 meter; IM-20-041: 7.18 g/t Au over 4.75 meters; IM-20-043: 12.36 g/t Au over 6.75 meters including 40.60 g/t Au over 0.75 meter; IM-20-050: 46.60 g/t Au over 0.85 meter; IM-20-053: 22.76 g/t Au over 7.00 meters including 47.00 g/t Au over 1.50 meters; IM-20-053: 24.73 g/t Au over 2.50 meters including 59.70 g/t Au over 1.00 meter; IM-20-059: 28.10 g/t Au over 1.50 meter; IM-20-059: 9.31 g/t Au over 6.00 meters; IM-20-061: 23.70 g/t Au over 1.50 meters. Mineralized quartz veins on Cariboo are overall sub-vertical dip and northeast strike. Vein corridors are defined as a high-density network of mineralized quartz veins within the axis of the last folding event's folds and hosted within a brittle meta-sandstone or calcareous meta-sandstone. Vein corridors are modelled at a minimum thickness of 2 meters and average about 4.5 meters true width. Individual mineralized veins within these corridors have widths varying from centimeters to several meters and strike lengths from a few meters to over 50 meters. These corridors have been defined from surface to a vertical depth averaging 300 meters and remain open for expansion at depth and along strike. Gold grades are intimately associated with quartz vein-hosted pyrite as well as pyritic, intensely silicified wall rock haloes in close proximity to the veins. True widths are estimated to be 60% to 75% of reported core length intervals. Intervals not recovered by drilling were assigned zero grade. Top cuts have not been applied to high grade assays.

09:22 EDT UPS says 'confident' domestic margin will expand in 2021 - Says "confident" in operating leverage going forward. Says continues to invest in time and transit. Expects to increase weekend delivery. Says first allocation of capital will be into the business. Says "committed" to the dividend and "improving flexibility of the balance sheet."

09:19 EDT NCR and Google Cloud collaborate on digital transformation in banking - NCR Corporation (NCR), and Google (GOOG) Cloud announced a global strategic partnership. Under the terms of the agreement, NCR will expand cloud availability of its Digital Banking software portfolio, including NCR Channel Services for retail banking as well as its card and payments processing platform NCR Authentic. "This initiative expands the cloud deployment options for NCR's customers, making it easier and faster for financial institutions to bring new digital banking services to market and accelerate digital transformations with confidence," said Frank Hauck, President and General Manager of NCR Banking. "Financial institutions will benefit from NCR's depth of banking industry experience along with the trusted, secure cloud platform provided by Google Cloud." NCR and Google Cloud will collaborate on product development and innovation to further enhance the suite of cloud-based solutions and analytics available to banking customers on Google Cloud. Google Cloud is a leading infrastructure, platform and industry solutions provider, helping businesses solve their most critical problems across 200 countries. With the ubiquitous Google Cloud, NCR's customers will gain a leading solution for powerful computing, data storage and powerful analytics, and business insight. "We're partnering with NCR to help accelerate the digital transformation of financial services organizations," said Derek White, vice president, Global Financial Services at Google Cloud. "Bringing NCR's widely adopted digital banking software onto Google Cloud means financial institutions can leverage scalable, secure cloud infrastructure, with the flexibility to deploy new, cloud-native solutions across on-premises, hybrid cloud, and as-a-service models, enabling them to deliver exceptional customer experiences."

09:19 EDT Ampio announces results from AP-014 Phase I clinical trial - Ampio Pharmaceuticals revealed positive results in its AP-014 Phase I clinical trial utilizing inhaled Ampion in treating respiratory distress in patients as a result of COVID-19. All patients in the study have now completed treatment, including a follow-up at Day 28 after treatment. The study not only met its primary endpoint, the final data showed an even greater improvement in all-cause mortality over patients treated using Standard of Care (SOC) than initially reported. Mortality in the SOC group was 24%, while that in the group treated with SOC and Ampion was only 5%, a 78% improvement in all-cause mortality. Preliminary results had been reported in March as 21% for SOC and 8% for Ampion, or a 62% improvement.

09:16 EDT Xilinx announces full production shipments of 7nm Versal AI Core, prime devices - Xilinx, announced that its Versal AI Core and Versal Prime series devices are now shipping to customers in full production volumes. Additionally, the third series in the Versal portfolio, Versal Premium, has now shipped to multiple tier-one customers through the company's early access program. Versal is the industry's first adaptive compute acceleration platform. Versal ACAPs combine scalar processing engines, adaptable hardware engines, intelligent engines with leading-edge memory and interfacing technologies to deliver powerful heterogeneous acceleration for any application beyond the capabilities of an FPGA. The Versal AI Core series delivers the highest compute and lowest latency in the Versal portfolio, enabling breakthrough AI inference throughput and performance through its AI engines. Versal AI Core is optimized for compute-intensive applications primarily for the data center, 5G wireless, and A&D markets, including machine learning and advanced signal processing. Customers have deployed Versal AI Core to accelerate workloads such as 5G gNodeB base stations, satellite-based broadband services, and audio-video bridging in 3D immersive stadium sports videos.

09:15 EDT NortonLifeLock, National PTA expand partnership - National PTA and NortonLifeLock announced an expansion of their partnership to engage more families and ensure equity in cyber safety conversations. With a new $1M commitment from NortonLifeLock, over the next two years National PTA will more than triple the amount of grant funding to local PTAs provided through NortonLifeLock, as well as modernize and relaunch The Smart Talk, a free, interactive tool and educational program originally created five years ago by National PTA and NortonLifeLock. The Smart Talk helps families address privacy, screen time, social media etiquette, app usage, texting and calling, and set tech ground rules for their household.

09:12 EDT Beyond Meat launches new Beyond Burger at grocery stores nationwide - Beyond Meat announced that the new version of its iconic Beyond Burger will arrive in grocery stores nationwide beginning the week of May 3rd. The latest and greatest Beyond Burger, which offers impressive advancements in taste and nutrition, will be sold in a 2-pack, the brand's first-ever value 4-pack and a 1lb. Beyond Beef pack.

09:11 EDT General Electric will continue to explore options in and around insurance

09:10 EDT Blue Water Acquisition Corporation (Class A Stock) trading resumes

09:09 EDT Edgewise Therapeutics appoints Joanne Donovan as CMO - Edgewise Therapeutics (EWTX) announced the appointment of Joanne Donovan to the position of CMO. Donovan will be responsible for leading clinical, medical and regulatory strategy and operations for the company's pipeline, including EDG-5506, the company's lead product candidate that is advancing in clinical development for Duchenne and Becker muscular dystrophy, or DMD and BMD. Prior to joining Edgewise, Donovan served as CMO and senior VP, clinical development at Catabasis (CATB). In this role, Donovan led clinical development in DMD from first-in-human through Phase 3 studies and New Drug Application preparation.

09:09 EDT Cyclerion Therapeutics announces highlights from webinar on CY6463 - Cyclerion Therapeutics hosted a webinar to provide clinical updates for its first-in-class, CNS-penetrant soluble guanylate cyclase stimulator CY6463 in Alzheimer's Disease with Vascular pathology and Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes. Supported by recent clinical and preclinical data, Cyclerion also discussed the potential for CY6463 to treat Cognitive Impairment Associated with Schizophrenia, with key insights from Dr. Andreas Reif on the role of the sGC pathway in the disease. In addition, Cyclerion introduced its latest development candidate CY3018, a differentiated, next-generation, CNS-penetrant sGC stimulator. Modulating a fundamental CNS signaling pathway: sGC stimulators amplify the power of the nitric oxide-soluble guanylate cyclase-cyclic guanosine monophosphate pathway signaling to address central aspects of disease pathophysiology. Preclinical data from CY6463 and extensive academic work validate the crucial role of the sGC pathway in brain physiology. Clinical data from the recent translational pharmacology study confirm the ability of CY6463 to impact brain oscillations, neuroinflammation and neurophysiological function. CY6463 Updates: Disease-relevant, biomarker-guided pipeline strategy: The company is advancing parallel, signal-seeking, exploratory studies in well-defined patient populations with cognitive impairment including neurodegenerative, neuropsychiatric, and mitochondrial diseases. CY6463 targets sGC, a proven druggable target, in critical brain regions and cell types linked to cognition and has demonstrated an impact on multiple biomarkers associated with cognition in previous Phase 1 studies. ADv clinical trial initiation: The U.S. Food and Drug Administration cleared the Investigational New Drug (IND) application for CY6463 in ADv, and the Company anticipates beginning to enroll patients in a 12-week Phase 2a clinical trial in patients with ADv by mid-2021, barring any COVID-19 related delays. This exploratory study is designed to evaluate safety, tolerability, and pharmacodynamic effects including impact on disease-relevant biomarkers. MELAS clinical trial advancement: This study is enrolling more slowly than initially projected, primarily due to COVID-19. Data from the exploratory 29-day open-label Phase 2a pilot study in patients with MELAS are now expected by year end 2021. Potential to treat CIAS with novel mechanism: Neuropsychiatric key opinion leader and expert in the neurobiology of nitric oxide and its relation to psychiatric disorders, Andreas Reif, M.D., Chair, Department of Psychiatry, University Hospital Frankfurt, discussed the sGC pathway and its role in cognitive function and CIAS. Reduced NO-sGC-cGMP signaling is linked to cognitive dysfunction in schizophrenia. Stimulation of sGC by CY6463 to amplify NO-sGC-cGMP signaling is a potential first-in-class approach for the treatment of CIAS. Cyclerion is planning to initiate a Phase 1b signal-seeking study in CIAS to evaluate safety and near-term impact on disease-relevant biomarkers. CY3018, a differentiated, next-generation CNS-penetrant sGC stimulator: Cyclerion shared information on the latest development candidate, CY3018. Preclinical data show increased CNS-exposure, with significantly increased cerebrospinal fluid to plasma ratio, compared to CY6463. This increased CNS distribution is mirrored by a higher level of pharmacological activity in the CNS relative to the periphery. The company is advancing CY3018 through IND-enabling development. Cash, cash equivalents, and restricted cash balance on March 31, 2021 was approximately $45 million, as compared to approximately $58 million on December 31, 2021. As of April 2021, Cyclerion has substantially streamlined its operating model to invest more fully in its priority opportunities in cognition and expects average monthly cash use for the foreseeable future to be approximately 50 percent that of 2020.

09:07 EDT Easterly Government Properties acquires USAO facility in Illinois - Easterly Government Properties announced that it has acquired a 43,600 leased square foot United States Attorney's Office, or USAO, facility in Springfield, Illinois. USAO - Springfield, a three-story build-to-suit construction for the Department of Justice United States Attorney's Office for the Central District of Illinois, was constructed in 2002 and is 100% leased to the General Services Administration, or GSA, on behalf of the USAO pursuant to a 20-year lease, which does not expire until March 2038. USAO - Springfield is located on the same block as the United States District Courthouse, serves as the headquarters for the USAO's Central Division of Illinois with subordinate staffed offices in Peoria, Rock Island and Urbana. The district includes 46 of the 102 counties within the State of Illinois.

09:06 EDT CN appoints Roberta Louise Jamieson, Murray Sinclar as co-chairs of IAC - The Board of Directors of CN is pleased to announce that Ms. Roberta Louise Jamieson, OC, Kanyen'keha:ka, and the Honourable Murray Sinclair, Mizanay Gheezhik, have accepted to Co-Chair the CN Indigenous Advisory Council, an independent body comprised of Indigenous peoples' representatives from across the country. The Council's mandate is to provide advice to the members of CN's Board and President and CEO on issues that are relevant to CN and its relationship with the over 200 Indigenous communities in which CN operates. The goals of the IAC include reinforcing diversity and inclusion through policies and procedures that reflect these values, as well as fostering meaningful and long-lasting relationships between the railway and Indigenous peoples.

09:04 EDT Infrastructure and Energy Alternatives awarded $50M wind construction contract - Infrastructure and Energy Alternatives announced that the company has been awarded the Plymouth Wind Energy Center contract valued at approximately $50M. Invenergy awarded this project to IEA Constructors, a subsidiary of IEA that manages utility-scale renewable energy and heavy civil infrastructure projects. The award is for the construction of a 200 megawatt utility-scale wind farm in northwest Iowa. Work on the Plymouth Wind Energy Center began in April and is expected to be completed in late 2021. IEA will self-perform all of the engineering, procurement and construction needs of the project, including the construction of project roads, installation of foundations, offloading of equipment and erection of 73 GE wind turbine generators.

09:03 EDT SS&C amnends offer to acquire Mainstream group - SS&C Technologies Holdings announced that it has amended the Scheme Implementation Deed with Mainstream Group Holdings to provide for an acquisition by SS&C of 100% of the shares and outstanding equity rights in Mainstream for A$2.25 per security pursuant to a scheme of arrangement. In the absence of a superior proposal, and subject to the independent expert concluding that the revised scheme is in the best interests of Mainstream shareholders, being customary carve-outs, the board of directors of Mainstream intends to support the revised scheme of arrangement on that basis. SS&C has agreed to increase the consideration payable under the scheme after receipt by Mainstream of a non-binding indicative cash offer of $2.20 per security from a third party. As a consequence of such increase and related amendments, Mainstream has terminated any discussions with such third party. Terms of the proposed acquisition imply an enterprise value for Mainstream of approximately A$332M or approximately $259M, including transaction costs and net debt. The purchase will be subject to customary conditions, including approval by Mainstream shareholders, the relevant Australian court and certain regulatory approvals, and is expected to close in the Q3. Mainstream is being advised by Miles Advisory Partners as financial adviser and Maddocks as legal adviser. SS&C is being advised by Citi as financial adviser and Gilbert + Tobin as legal adviser.

09:02 EDT eXp World Holdings expands real estate operations into Columbia - eXp World Holdings has expanded into Colombia, under the eXp Colombia banner. eXp Realty now operates in 14 countries and territories with more than 50,000 agents across the globe. eXp Realty's worldwide expansion is being led by Michael Valdes, President of eXp Global and an international real estate veteran with experience opening markets around the world. eXp Colombia's brokerage operations will be led by Santiago Carrizosa, Managing Broker, eXp Colombia. Colombia represents the first of the three markets that eXp Global has identified for expansion in the second quarter of 2021, with the openings of Spain and Israel slated to open later in the quarter. Puerto Rico, Brazil, Italy and Hong Kong opened eXp operations in the first quarter of 2021.

09:02 EDT Trivago collaborates with TUI to offer activities feature - trivago announced a collaboration with TUI Group to provide trivago users with direct access to more than 55,000 excursions, activities and tickets. As trivago's activities partner, TUI will power the new 'Activities' section on the trivago website. trivago users will have direct access to a diverse portfolio of experiences, from guided tours and tickets for world renown landmarks and attractions, such as the One World Observatory, Colosseum and Harry Potter Studios, to unique activities, including sunset stadium climbs and double-decker bus dining. The majority of experiences will have immediate email confirmation and can be cancelled up to 24 hours before they start, offering peace of mind when booking.

08:57 EDT IBM boosts quarterly dividend to $1.64 per common share - The IBM board of directors boosts dividend to declared an increase in the regular quarterly cash dividend to $1.64 per common share, payable June 10to stockholders of record as of May 10. IBM has paid consecutive quarterly dividends since 1916.

08:53 EDT GE sees strong trends in offshore wind market continuing through decade

08:43 EDT IntercontinentalExchange debuts ultra-low latency wireless services in Europe - Intercontinental Exchange announced the launch of its ultra-low latency wireless market data offering in the London metro area and Frankfurt by ICE Global Network, IGN. Connectivity, speed and reliability are essential for market participants. IGN provides customers with an abundance of data and connectivity to more than 150 capital market venues and 750 native market feeds. The addition of wireless market data services in Europe will offer customers a new choice of provider and expand market data options for all customers. With competitive latencies connecting customers quickly and efficiently to select global markets, this offering also appeals to firms seeking diversity from private networks. IGN will leverage existing wireless infrastructure in Europe to help customers meet the increasing demands they face to make decisions in fractions of seconds. The wireless market data offering will allow clients to access both cash and derivatives packages in the London triangle from ICE Futures, Euronext, CBOE Europe and LSE, as well as Eurex and Xetra from Frankfurt. The use of this reliable wireless network will allow customers to leverage the benefits of a highly optimized wireless service to help enhance their trading performance.

08:43 EDT General Electric: Healthcare orders continue to improve

08:42 EDT 3D Systems announces VSP Hybrid Guides - 3D Systems announced VSP Hybrid Guides - the latest enhancement to its VSP surgical planning solutions portfolio. "This first-to-market solution for maxillofacial surgeons combines the strength of titanium with the relative softness of nylon in a single patient-specific guide with registration to the dentition for added confidence in guide placement and surgical site visibility. This latest innovation was engineered in response to customer feedback and demonstrates 3D Systems' commitment to driving better outcomes for maxillofacial and reconstructive surgeons and their patients... Tooth-based registration is achievable with nylon material, and the profile advantages of a rigid metallic cutting and drilling guide are preserved. The new guides are assembled with easy-to-use connection sites that are engineered to confirm a proper connection. Depending on the surgeon's preference, patient-specific instruments can be designed that allow multiple cutting/drilling locations on a single occlusal-based guide. A secondary benefit of using occlusal registration is the potential for a reduced guide footprint. The slimmer profile guides not only provide easier placement in areas with limited exposure but also improve a surgeon's visibility of the surgical site," the company said.

08:40 EDT Iteris, Continental enter pact to explore intelligent infrastructure solutions - Global mobility supplier Continental and Iteris announced they have entered into a collaboration agreement to explore intelligent infrastructure solutions for communities across North America. With the goal of readying cities for advancements in connected and automated vehicle technologies, the partnership is designed to help ensure safer and more efficient mobility. The future-oriented traffic infrastructure collaboration will leverage automotive sensors and infrastructure-to-vehicle, or I2V, connectivity to make city transportation systems across North America more efficient, while supporting local and regional transportation agencies' efforts to achieve their Vision Zero goals. Information generated by the automotive sensors will be used to enable collective perception capabilities. In addition to sharing a connected vehicle's location with other V2X-enabled devices, collective perception messaging enables that vehicle to also share what it senses with the rest of its connected environment. The collaboration is focused on improving the current transportation infrastructure while working toward a more balanced, intelligent and optimized infrastructure that communicates seamlessly with the mobility ecosystem in the future thanks to expanded sensing capabilities.

08:39 EDT Predictive Oncology announces Christina Jenkins as new board member - Predictive Oncology announce their newest board member Dr. Christina Jenkins. Jenkins is a strategic advisor and venture investor whose expertise spans clinical medicine, venture capital, health systems and health plans. Jenkins is a Venture Partner at Phoenix Venture Partners, where she co-leads the firm's seed-stage investment strategy in the healthcare/life sciences vertical. She is a board director for Independence Health Group, a board Observer for Madorra, and an advisory board member of multiple value-generating healthcare companies.

08:38 EDT Generex receives $2M development payment from Beijing Youfeng Biological - Generex Biotechnology Corporation announced that in connection with its partnership with the National Institute for Viral Disease Control and Prevention, Chinese Centre for Disease Control and Prevention, Beijing Youfeng International Consulting Co., Ltd and Beijing Guoxin Haixiang Equity Investment Partnership, the company has received a $2 million development payment from Beijing Youfeng Biological Technology. In exchange for this payment, Generex will provide to Youfeng-BI and our Chinese partners research results, data, regulatory documents, and manufacturing methods to support the filing of an Investigative New Drug application for the Ii-Key-SARS-CoV-2 Vaccine in China. Pursuant to the partnership, the company's partners in China are responsible for the development and regulatory approval of the Ii-Key COVID Vaccine by the NMPA in China. All clinical trials will be conducted under guidelines of the International Council on Harmonisation, so the data can be used for submission to FDA, EMEA, and other international regulatory agencies; Generex Biotechnology Corporation and NuGenerex Immuno-Oncology maintain the rights to the Ii-Key-SARS-CoV-2 Vaccine in the rest of the world outside China. Generex will coordinate technology transfer with the Chinese partners to facilitate research and development efforts required to achieve the commercial approval of a Complete Vaccine in China. A complete vaccine is designed to regulate the immune system to provide a targeted, neutralizing antibody response without generating off-target, non-neutralizing antibodies that can lead to antibody dependent enhancement of disease; further a complete vaccine should activate the appropriate T cell responses to yield long-term immune memory without activating detrimental Th2 responses that have been associated with immune-related complications of COVID-19 disease. NuGenerex Immuno-Oncology has filed for and expects to receive a trademark for The Complete Vaccine and has filed patent applications for the Ii-Key-SARS-CoV-2 Vaccine and Ii-Key Vaccine platform.

08:37 EDT OSI Systems IDIQ contract for up to $480M - OSI Systems, announced that its Security division was one of three vendors awarded an indefinite delivery, indefinite quantity contract by the U.S. Customs and Border Protection for multi-energy portal x-ray systems, including installation and training. The IDIQ contract has a potential value of up to $480M and contains a five-year ordering period for systems and up to ten years for potential maintenance support. "We are excited to receive this IDIQ award and look forward to supporting CBP's non-intrusive inspection program," said Deepak Chopra, OSI Systems' Chairman and CEO.

08:35 EDT Hess Corp. announces oil discovery at Uaru-2, offshore Guyana - Hess announced another oil discovery offshore Guyana at the Uaru-2 well on the Stabroek Block, which will add to the previously announced gross discovered recoverable resource estimate for the block of approximately 9 billion barrels of oil equivalent. Uaru-2 encountered approximately 120 feet of high quality oil bearing sandstone reservoir, including newly identified intervals below the original Uaru-1 discovery. The well was drilled in 5,659 feet of water and is located approximately 6.8 miles south of the Uaru-1 well. "The Uaru-2 discovery will add to the discovered recoverable resource estimate of approximately 9 billion barrels of oil equivalent," CEO John Hess said. "We expect to have at least six FPSOs on the Stabroek Block by 2027, with the potential for up to 10 FPSOs to develop the current discovered recoverable resource base." Production from the Liza Phase 1 development on the Stabroek Block utilizing the Liza Destiny FPSO reached its nameplate capacity of 120,000 gross barrels of oil per day in December 2020 and remained at this level during the first quarter of 2021. In mid April, production from the Liza Destiny was curtailed for several days after a minor leak was detected in the flash gas compressor discharge silencer. Production has since ramped back up and is expected to remain in the range of 100,000-110,000 gross barrels of oil per day until repairs to the discharge silencer are completed in approximately three months. Following this repair, production is expected to return to, or above, nameplate capacity.

08:34 EDT CohBar appoints Joseph Sarret as CEO and director - CohBar announced the appointment of Joseph Sarret, M.D., J.D. as CEO and director, effective May 3, 2021. The board of directors expresses appreciation for the contribution of Steven Engle during his tenure as CEO and director of the company. In addition, David Greenwood, a current director with 40 years of financial and operational experience in biotechnology and investment banking, has assumed the role of chairman of the board. In connection with his appointment as CEO, CohBar announced it has granted Dr. Sarret equity awards that were approved by the Compensation Committee of its board of directors, with a grant date of May 3, 2021, as a material inducement to employment. CohBar granted Dr. Sarret an option to purchase 2,600,000 shares of CohBar common stock. One-fourth of the shares underlying this option will vest on May 3, 2022 and thereafter 1/48th of the shares underlying the option will vest monthly, such that the shares underlying the option will be fully vested on May 3, 2025, subject to Dr. Sarret's continued employment with CohBar on such vesting dates. Of the shares subject to the Time Based Grant, shares with a fair market value of $100,000 based on the closing price of CohBar's common stock on the effective date of the Time Based Grant will be issued pursuant to CohBar's Amended and Restated 2011 Equity Incentive Plan, and the balance of the shares subject to the Time Based Grant will be granted pursuant to the inducement grant. CohBar also granted Dr. Sarret as an additional inducement grant an option to purchase 1,300,000 shares of CohBar common stock, with a grant date of May 3, 2021, which will vest over a two-year period, subject to Dr. Sarret's continued employment with CohBar on such vesting dates and the achievement of certain performance metrics that will be determined by the Board no later than June 30, 2021. Each of the options will have an exercise price equal to the closing price of CohBar's common stock on May 3, 2021.

08:30 EDT Embraer delivers nine commercial, 13 executive jets in Q1 - Embraer delivered a total of 22 jets in the first quarter, of which nine were commercial aircraft and 13 were executive jets (10 light and three large). As of March 31st, the firm order backlog totaled $14.2B.

08:26 EDT NetSol Technologies signs multi-million-dollar renewal with Japanese customer - NETSOL Technologies announced that it has secured a multi-million-dollar renewal of its current agreement with an existing tier-one Japanese automotive customer in Thailand. Under the terms of the contract, this customer will continue to license certain key components of NETSOL's NFS Retail platform, including its NFS Credit Application Processing System and NFS Contract Management System. "This customer has been a market leader in the financing and leasing of commercial vehicles and pickup trucks in Thailand for some time, and we're looking forward to building our already-strong working relationship for years to come," said NETSOL President and Otoz CEO Naeem Ghauri. "Over the past few years, we've been able to provide clear value and quality for their operations, utilizing both the CAP and CMS components of our NFS Retail platform. On a broader level, this renewal further solidifies our standing in Thailand and across Asia-Pacific as the preferred business partner for auto captives and finance and leasing companies in the region."

08:23 EDT Lottery.com enters partnership with Countable - Lottery.com announced that its charitable sweepstakes platform, WinTogether Trust, has entered into an agreement with Countable Corp. to reimagine the future of engaging communities online for WinTogether's charitable initiatives. Together, Countable and WinTogether aim to propel financial success for top tier organizations at the nexus of social impact issues, such as sustainability, social justice, and education. WinTogether and Countable plan to bring visibility and engagement through dedicated hubs for each charitable campaign. Social content will be shared across the WinTogether site, powered by Countable, and via Causes.com, a service division of Countable, with a broad audience of 192M followers. Content will be tailored to targeted Causes.com audience cohorts in an effort to effectively amplify key messages and drive impact for WinTogether philanthropy.

08:21 EDT KVH Industries introduces P-series IMUs with PIC technology - KVH Industries announced that it has introduced the P-1750 IMU and the P-1725 IMU to complement the previously released P-1775 IMU and create a full line of IMUs that feature high-performance accelerometers and KVH's patented photonic integrated chip technology. The KVH P-series IMUs are offered in the same proven, compact IMU housing design, and now offer more dynamic and accurate sensor performance delivering improved navigation capability and more environmental robustness in vibration and shock capability for more challenging applications.

08:20 EDT Lakeland Bancorp board authorizes annualized 8% increase in cash dividend - CEO Thomas Shara said, "The quarterly results were record earnings for Lakeland which were bolstered by an 11 basis point increase in our net interest margin and an increase in pre-tax income. Considering our continued success, the Board authorized an annualized 8% increase in our cash dividend."

08:18 EDT General Electric sees Industrial free cash flow growth in Q2 similar to Q1 - Comments taken from Q1 earnings conference call.

08:15 EDT Revance says 1st patient enrolled for DaxibotulinumtoxinA study by Fosun Pharma - Revance Therapeutic announced that Shanghai Fosun Pharmaceutical Industrial Development, Fosun Pharma Industrial, a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical has initiated Phase 3 trials of DaxibotulinumtoxinA for Injection in China, for the treatment of glabellar lines and cervical dystonia. Both trials enrolled and dosed their first patients in April. China is a fast-growing market for neuromodulators, with an estimated aesthetics and therapeutics opportunity of $318 million in 2021 that is projected to increase to $762 million by 2027, 15.7% CAGR. "The initiation of Phase 3 clinical trials for the treatment of glabellar lines and cervical dystonia marks an important advancement in our international expansion efforts and partnership with Fosun Pharma," said Mark J. Foley, President and Chief Executive Officer at Revance. "Fosun Pharma is a leading pharmaceutical and healthcare company in China and we look forward to continuing our collaboration with them in order to bring our next-generation product to the second largest neuromodulator market in the world." Revance entered into a license agreement with Fosun Pharma Industrial in 2018, whereby Fosun Pharma Industrial received exclusive rights to develop

08:14 EDT VistaGen Therapeutics announces appointment of Joanne Curley to board - VistaGen Therapeutics announced the appointment of Joanne Curley, Ph.D. to its board of directors. Following the appointment of Doctor Curley, VistaGen's board will be comprised of seven directors. "Joanne brings more than 25 years of pharmaceutical industry experience across numerous key operational and therapeutic areas," said Shawn Singh, CEO of VistaGen. "Her track record of propelling seven products from early development through regulatory approval is impressive and reflects her extensive experience and understanding of the entire life cycle of drug development. As we expand our business and pursue our mission to improve mental health and well-being for individuals in the U.S. and abroad, her tremendous leadership, creativity and expertise will be invaluable to VistaGen."

08:13 EDT Scotts Miracle-Gro announces 2021-2025 ESG business goals - The Scotts Miracle-Gro Company announced its new environmental, social and governance-driven business goals that will guide the company's sustainability strategy over the next five years. The goals, which were revealed with the release of ScottsMiracle-Gro's 2021 Corporate Responsibility Report, outline how the company will deliver on its corporate purpose--to GroMoreGood everywhere--for associates, communities, consumers and the environment throughout 2021 and beyond. ScottsMiracle-Gro has intensified its actions to align business practices over the past decade in ways that are good for the planet, people and communities. During 2019-2020, the company underwent a formal materiality assessment, following the guidelines of the Global Reporting Initiative, to prioritize its most important ESG opportunities and risks and to further align its sustainability goals and commitments with stakeholder priorities. Based on that assessment, five key areas of focus were identified to drive ScottsMiracle-Gro's sustainability strategy over the next five years: Product Stewardship and Safety; Operations and Supply Chain; Associate Engagement and Wellness; Community Engagement; Governance and Transparency. Some highlights from ScottsMiracle-Gro's recently announced ESG goals featured in their 2021 Corporate Responsibility Report include: Community Engagement: Connecting 10 million children to the benefits of gardens and greenspaces; Reaching 145 million Americans through environmental partnerships; Investing $2.5 million in criminal justice reform and economic inclusion initiatives within the cannabis space. Product Stewardship and Safety: Tripling the amount of recycled content in plastic packaging; Increasing consumer brand packaging that can be recycled or reused by 50%. Operations and Supply Chain: Utilizing established data collection process for emissions and waste in 100% of locations to establish baseline metrics and future improvement goals; Demonstrating improvement on identified "GroMoreGood" Goals among 75% of suppliers/ Associate Engagement and Wellness: Applying diagnostic data to identify strengths and areas of opportunity in the company's mission to ensure all associates are treated in a fair and equitable manner Continuing to provide holistic health and wellness programs to help people through their best and most challenging times, with the goal of enhancing their health, happiness and longevity.

08:11 EDT AssetMark Financial launches alternative investments by iCapital Network - AssetMark and iCapital Network announced the launch of AssetMark Alternative Investments by iCapital, a customized alternative investments service on the AssetMark platform. The solution provides a "curated selection of fully diligenced alternative investments with low minimums and a seamless end-to-end investing experience to support independent advisors in attracting and serving high-net-worth clients," the company said. AssetMark Alternative Investments augments the investment solutions available to independent registered investment advisors, or RIAs, on the AssetMark platform with alternative investment strategies designed to "address the diversification and return objectives of qualified HNW investors. The offering provides access to alternative investment managers professionally diligenced by iCapital, through a convenient, best-in-class user experience. It features an integrated, single sign-on with automated subscription and administration, document management, and reporting," the company stated.

08:11 EDT Comscore to expand agreement with ViacomCBS - Comscore (SCOR) announced an expanded renewal agreement to provide ViacomCBS (VIAC) with Comscore's National TV measurement currency for its leading portfolio of news, entertainment and sports networks. Comscore's partnership with ViacomCBS linear television measurement began in 2014 and quickly expanded to develop advanced audiences to support Viacom's industry leading Vantage Platform. The new, expanded agreement goes beyond advanced advertising, and will enable ViacomCBS to guarantee its traditional linear advertising campaigns on Comscore's National TV currency, a key element as the media and entertainment company looks to diversify its partnerships around measurement across both its linear and digital assets.

08:09 EDT Duluth Holdings appoints Sam Sato as president and CEO - Duluth Holdings has appointed retail industry veteran Samuel Sato as president and CEO, effective May 3, 2021. Sato will succeed founder Steve Schlecht who has guided the company as CEO since September 2019. Sato will report directly to the board of directors, and it is anticipated Sato will also become a member of the board on May 27, 2021. Also effective on May 27, 2021, Schlecht intends to transition to non-executive chairman of the board.

08:07 EDT WiMi Hologram Cloud obtains patent for HMD for holographic AR systems - WiMi Hologram Cloud announced that it has obtained a patent for head-mounted display for holographic AR systems. This patent is the result of the independent research and development, which is conducive to further improve the intellectual property protection system, maintain the leading position in technology and enhance the core competitiveness of the company.

08:07 EDT UiPath appoints Bettina Koblick Chief People Officer - Enterprise automation software company, UiPath announced the appointment of Bettina Koblick as its Chief People Officer. Koblick will report directly to UiPath co-founder and CEO Daniel Dines and will lead all aspects of the people function, from employer brand to talent acquisition through the entire employment lifecycle. Andreea Baciu, UiPath interim CPO, will become the Company's first Chief Culture Officer, reporting to Koblick and continuing to be part of Dines' leadership team. In this role, Baciu will work across the organization to continue building a winning team and nurturing a culture of belonging that aligns UiPath global inclusion and diversity goals with business outcomes. Koblick joins UiPath from ServiceMax where she served as Chief People Officer. She brings to UiPath deep experience based on her time with software companies that varied in scale and stage, from small private startups to Fortune 500 firm Symantec.

08:06 EDT Medtronic receives approval from FDA to evaluate its TNM - Medtronic announced approval from the FDA to proceed with an investigational device exemption, or IDE, trial to evaluate its internally developed implantable tibial neuromodulation, or TNM, device - a therapy designed to provide relief from symptoms of bladder incontinence. The TITAN 1 Feasibility Study is a prospective, multicenter, feasibility study to characterize the procedure for the implantable TNM device in subjects with bladder incontinence.

08:05 EDT Establishment Labs completes enrollment in Motiva Mia case series in Costa Rica - Establishment Labs announced it has completed enrollment in its one hundred patient Motiva Mia case series in Costa Rica. The Institutional Review Board, or IRB, approved study began in December 2020 and follows the initial 2019 case series in Asia. Establishment Labs also announced that is has submitted the tools used in the Motiva Mia breast enhancement procedure for CE mark. Fifteen board-certified plastic surgeons from Costa Rica, Sweden, England, Brazil, Austria, Italy, Belgium, and the United States participated in the case series. The single-center study is a prospective, interventional, single-arm, feasibility study of women 18 years or older in primary minimally invasive breast enhancement.

08:04 EDT Sephora, Kohl's announce brands to debut in retail partnership this fall - Sephora, in partnership with Kohl's, announced more than 125 prestige beauty brands will be coming to Sephora at Kohl's this August as part of their new omni partnership. The curated Sephora at Kohl's assortment, available on Kohls.com and initially in 200 Kohl's stores in 2021, will have some of the most recognizable and coveted brands in makeup, skincare, hair, and fragrance and featured categories like Clean at Sephora. Some of the brands customers will discover include: Anastasia Beverly Hills, Benefit Cosmetics, Charlotte Tilbury, Fenty Beauty, ILIA, Lancome, Makeup By Mario, Make Up For Ever, Milk Makeup, NARS, Rare Beauty, Tarte, Too Faced, Drunk Elephant, Estee Lauder, Fenty Skin, Fresh, Glow Recipe, Kate Somerville, Ole Henriksen, Sol de Janeiro, Summer Fridays, Supergoop, Tatcha, The Ordinary, Youth to the People, Bumble and bumble, Briogeo Hair Care, Drybar, Olaplex, Armani, Gucci, Maison Margiela, Tom Ford, Viktor & Rolf, Yves Saint Laurent.

08:02 EDT Chesapeake CEO Doug Lawler departs, Mike Wichterich named interim CEO - Chesapeake Energy announced the departure of Doug Lawler from his position as CEO of Chesapeake, effective April 30. Mike Wichterich, the Chair of Chesapeake's Board of Directors, will serve as Interim CEO while the Board of Directors conducts a search for a new CEO, which it expects to complete over the coming months.

07:56 EDT Garmin International, WellTeq launch health and wellness solution - Wellteq Digital Health is pleased to announce the Company has launched a comprehensive health and wellness solution in cooperation with Garmin International, Inc., a unit of Garmin and Singapore health and fitness leader UFIT. The combined services of Wellteq's employee wellness platform, Garmin wearables and UFIT's virtual and in-person health and fitness services - including group classes and 1:1 training sessions - caters to almost all employee wellness preferences and needs.

07:47 EDT PyroGenesis sings binding LOI to acquire AirScience Technologies for $4.8M - PyroGenesis Canada is pleased to announce that it has signed a binding Letter of Intent, which outlines the terms and conditions pursuant to which PyroGenesis would acquire AirScience Technologies Inc for $4.8MM. The LOI is binding on AST, but it is only binding on PyroGenesis if in its sole opinion, it is satisfied with the final due diligence currently in progress. The option to satisfy the Purchase Price in shares or cash is at the sole discretion of the buyer, and will only be made on, or about, final closing. AST is a Montreal-based company that designs and builds gas upgrading systems, Pyrolysis-Gas Purification, Coke-Oven Gas Purification as well as providing Biogas & Landfill-Gas Flares and Thermal Oxidizers.

07:46 EDT Equifax and Revolut announce new strategic relationship - Equifax and global fintech Revolut announced a new strategic relationship. Used by more than 15M people globally to make over 100M transactions a month, Revolut has selected Equifax to better serve its customers in the United States and provide a more diverse range of services. Equifax was chosen for the ability to provide cloud-native differentiated data assets and real-time predictive analytics for a faster, more informed view of customers and prospects.

07:43 EDT WPD Pharmaceuticals to present assumptions of WPD-201P Clinical Trial Protocol - WPD Pharmaceuticals is pleased to announce that it will attend the 10th Annual Congress of the Polish Society of Pediatric Oncology and Hematology to be held on May 6-8, 2021. During the Congress, WPD will present the key assumptions of the WPD-201P Clinical Trial Protocol, which is planned to start in Q2 2021, as a part of the research project: "New approach to glioblastoma treatment addressing the critical unmet medical need", granted by National Research and Development Center and co-financed by the European Union, under the Smart Growth Operational Program 2014-2020. Berubicin is a second-generation anthracycline candidate for the treatment of a number of Central Nervous System Cancers, including Glioblastoma Multiforme and Malignant Gliomas. Anthracyclines are designed to utilize natural processes to induce deoxyribonucleic acid damage in targeted cancer cells by interfering with the action of topoisomerase II, a critical enzyme enabling cell proliferation. Berubicin was developed by Dr. Waldemar Priebe, Professor of Medicinal Chemistry at The University of Texas MD Anderson Cancer Center, and demonstrated positive responses that include one durable complete response in a Phase 1 human clinical trial conducted previously by Reata Pharmaceuticals. WPD also announces it has engaged Strikepoint Media, to provide digital marketing and brand awareness support. The Company has agreed to pay Strikepoint $50,000 for a 3 month digital media term commencing on April 26, 2021. Strikepoint will not receive any securities of the Company as compensation for their services.

07:42 EDT Revival Gold commences trading on OTCQX Market - Revival Gold announces that its common shares are now trading on the OTCQX market in the United States under the ticker symbol "RVLGF". Revival Gold will continue to trade on the TSX Venture Exchange in Canada as its primary listing under the symbol "RVG".

07:38 EDT Tanzanian Gold announces James Sinclair retires as executive chairman - Tanzanian Gold announced it "would like to congratulate its founder, James Sinclair on recently turning 80 years old, and announce that Sinclair has retired as executive chairman to continue service as chairman of the board of directors for the company. TanGold has had the privilege of being founded and directed since 2000 by the leadership of the renowned James Sinclair. It is with profound gratitude that the company acknowledges his contribution to the present success and long-term resilience of our enterprise. The company is on the path to further achievements which stem from the foundation created by Sinclair."

07:32 EDT Aldeyra gets statistical significance for primary endpoint for reproxalap - Aldeyra Therapeutics announced positive top-line results from the Phase 3 INVIGORATE Clinical Trial of 0.25% reproxalap ophthalmic solution, reproxalap, an investigational new drug, in patients with allergic conjunctivitis. The clinical trial successfully achieved statistical significance for the primary endpoint and all secondary endpoints. "The statistically significant superiority of reproxalap over vehicle across all allergic conjunctivitis symptoms and signs assessed in INVIGORATE is remarkable, and suggests utility in one of the world's most common ocular surface diseases," stated Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra. "We believe the consistent activity observed across chamber models in allergic conjunctivitis and dry eye disease bodes well for the commercial positioning of reproxalap as potentially the only broadly applicable topical anterior segment immune-modulating drug that may be used for chronic treatment, if approved for marketing." The randomized, double-masked, vehicle-controlled, two-way crossover design allergen chamber Phase 3 INVIGORATE Trial enrolled 95 allergic conjunctivitis patients. The primary efficacy endpoint was change from baseline in subject-reported ocular itching score on a 0-4 point scale over a majority of 11 timepoints from 110 to 210 minutes after allergen chamber entry. The key secondary endpoint was change from baseline in ocular redness on a 0-4 point scale over the duration of the allergen chamber (approximately 3.5 hours).

07:30 EDT Aldeyra trading resumes

07:24 EDT LogicBio Therapeutics issues update on SUNRISE Phase I/II trial of LB-001 - LogicBio Therapeutics announced an update on screening and enrollment activities for the SUNRISE Phase I/II clinical trial of LB-001, the company's investigational treatment for methylmalonic acidemia based on LogicBio's proprietary gene insertion platform, GeneRide. "The first two patients who entered pre-dosing screening activities did not meet all of the enrollment criteria for the SUNRISE trial, each for different reasons, and we will continue to screen additional patients in the coming weeks," said Daniel Gruskin, M.D., senior vice president and head of clinical development at LogicBio. "With COVID-19 restrictions being lifted in some U.S. states, additional clinical trial sites have recently been activated and have begun recruiting and screening patients." "We expect to enroll our first patient in the SUNRISE trial by mid-year 2021, which represents a slight delay from our earlier communications," said Frederic Chereau, president and CEO of LogicBio. "We are also pleased to report that we have pre-identified enough patients to fully enroll SUNRISE, assuming a certain number of screening failures."

07:23 EDT Lantronix announces use of xDirect Server in development of Sickbay IoT solution - Lantronix announced that its xDirect Server was used in the development of Medical Informatics Corp.'s Sickbay solution, a single, FDA-cleared virtual care and analytics platform. Sickbay transforms data into actionable information to help patient care teams make better, faster decisions and save lives.

07:22 EDT Castle Biosciences to acquire myPath Laboratory from Myriad Genetics for $32.5M - Castle Biosciences (CSTL) announced it has signed a definitive agreement to acquire all of the equity of Myriad myPath from Myriad Genetics (MYGN). Myriad myPath Laboratory is a CLIA-certified laboratory in Salt Lake City, where the myPath Melanoma 23-gene expression profile, or GEP, test was developed and is currently owned and offered. Castle is acquiring Myriad myPath Laboratory for $32.5M. Castle will finance the acquisition price with cash and cash equivalents on hand. The transaction is expected to close approximately four weeks post signing, at which time Castle will be the successor owner of Myriad myPath Laboratory. The transaction is subject to customary conditions to closing. MyPath Melanoma is a clinically validated GEP test designed to be used as an adjunct to histopathology when the distinction between a benign nevus and a malignant melanoma cannot be made confidently by histopathology alone. Castle currently offers DecisionDx DiffDx-Melanoma, a 35-GEP test designed to characterize difficult-to-diagnose melanocytic lesions. MyPath Melanoma is a distinct test, which Castle anticipates will complement its current offerings.

07:21 EDT Finch Therapeutics appoints Susan Graf to board of directors - Finch Therapeutics announced that Susan Graf has joined Finch's board of directors and will serve as chair of the Audit Committee. Graf is a biopharma executive with more than 25 years of experience and currently serves as CEO of Akamara Therapeutics.

07:18 EDT Aravive announces first patient dosed in Phase 3 trial evaluating AVB-500 - Aravive announced the company has dosed the first patient in its Phase 3 trial of AVB-500 in platinum resistant ovarian cancer. The trial is evaluating the efficacy of AVB-500 in combination with paclitaxel and the primary endpoint is progression free survival. In the Phase 1b clinical trial, AVB-500 was well-tolerated with a favorable safety profile and had promising clinical responses in patients who achieved minimal efficacious concentration in a subset analysis, which supported the Phase 3 trial design. "Aravive has simplified the Phase 3 trial's statistical analysis plan to include a single prospectively defined interim analysis to determine whether randomization will continue with all patients, regardless of prior bevacizumab treatment, or only with patients medically ineligible to receive bevacizumab or who chose not to receive bevacizumab," the company said. The final analysis of the primary endpoint preserves the opportunity to evaluate the efficacy in patients who received bevacizumab prior to study entry, as well as those patients who never received bevacizumab. This provides an additional opportunity to be successful in both patient populations, regardless of the results of the interim analysis. Analysis of pretreatment serum sAXL/GAS6 will be conducted to determine whether it can identify patients who benefit from AVB-500 plus paclitaxel, but it will not be used in an interim analysis to select patients since the company believes the trial, which is expected to enroll 300-400 patients, is well-powered for the anticipated treatment effect without the need for biomarker enrichment. The primary endpoint of the trial remains progression free survival by RECIST 1.1, a standard method of assessing clinical activity in this patient population and the accepted regulatory endpoint for full approval. The secondary endpoint is overall survival.

07:16 EDT Lithia Motors acquires Planet Honda in Union, New Jersey - Lithia Motors & Driveway announced it has acquired one of the largest Honda dealerships in the country, Planet Honda, located in Union, New Jersey with expected annual revenues in excess of $200M. This purchase brings LAD's total annualized revenues acquired to over $6.7 billion since the launch of its five-year plan ten months ago. "We continue our accelerated pace of acquisitions and are well ahead of our target of acquiring $4 billion in annualized revenues each year," said CEO Bryan DeBoer. "With the most robust and active pipeline in our history, we expect 2021 to be a banner year as we progress toward our five-year plan of $50 billion in revenue and $50 earnings per share. "This transaction was financed using free cash flow and existing on-balance sheet capacity.

07:15 EDT Harbor Custom Development closes 23 developed lots for $1.72M - Harbor Custom Development announced that it has closed on 23 developed single family lots for $1.72M in the Siena Creek subdivision in Horseshoe Bay, Texas, located approximately 53 miles west of Austin. On March 10, 2021, Harbor Custom Homes announced entering a contract to acquire a total of 30 lots in Sienna Creek and now anticipates acquiring a total of 34. The 11 remaining lots are scheduled to close during the second and third quarters of 2021.

07:15 EDT Surface Oncology names Henry Rath CBO, Alison O'Neill CMO, Jessica Fees CFO - Surface Oncology announced the appointment of Henry Rath as chief business officer, and the promotions of Alison O'Neill, M.D. to chief medical officer and Jessica Fees to chief financial officer. Prior to joining Surface, Henry worked at TScan Therapeutics, Seres Therapeutics, Amgen, Catabasis and Baxter Biopharmaceuticals. Surface also announced the following internal promotions of key senior executives. Dr. Alison O'Neill, who joined Surface in 2018, to chief medical officer. Dr. O'Neill previously served as senior vice president of clinical development. Jessica Fees to chief financial officer. Ms. Fees has over 20 years of progressive experience and responsibility in finance and operations, including most recently serving as senior vice president of finance at Surface.

07:12 EDT LogicBio Therapeutics announces strategic collaboration with CANbridge Pharma - LogicBio Therapeutics announced a strategic collaboration and option agreement with CANbridge Pharmaceuticals, a biopharmaceutical company delivering life-changing therapeutics built upon a foundation in China. Under the terms of the agreement, CANbridge is granted an option to an exclusive license for LB-001, an investigational in-vivo gene editing technology based on LogicBio's GeneRide platform for the potential treatment of methylmalonic acidemia in Greater China. CANbridge would assume responsibility and costs for all future development, regulatory, commercial, and potentially manufacturing activities in the territory upon exercise of said option.The agreement also grants CANbridge a worldwide license for the adeno-associated virus sL65, the first capsid produced from LogicBio's sAAVyTM platform, and development support on gene therapy candidates for the treatment of Fabry and Pompe disease plus two optional indications. LogicBio is eligible to receive an upfront payment of $10M. This payment triggers the development of two gene therapy candidates for Fabry and Pompe disease based on AAV sL65. In addition, it grants options for a LB-001 license in Greater China and two additional undisclosed gene therapy programs. The agreement also includes options payments, clinical, regulatory and commercial milestone payments of up to $581 million and up to double-digit royalties on net sales.

07:12 EDT Myriad Genetics to sell Myriad myPath Melanoma Laboratory for $32.5M - Myriad Genetics (MYGN) announced that it has signed a definitive agreement to sell the Myriad myPath Melanoma Laboratory, which is the laboratory that offers the myPath Melanoma test, to Castle Biosciences (CSTL) for $32.5M in cash. Castle Biosciences is a specialty laboratory focused on advanced diagnostics for dermatologic cancers. myPath Melanoma has been used by almost 40,000 patients to guide treatment decisions and has been ordered by approximately 20% of dermatopathologists in the country. The deal is subject to customary closing requirements and Myriad expects the transaction to close in its fiscal second quarter.

07:10 EDT ADT Inc. brings trademark suit against Amazon's Ring - ADT (ADT) brought an action for willful trademark infringement, unfair competition, and related violations against Ring, an Amazon company (AMZN) and provider of smart home security devices. The company said, "In March 2021, the complaint asserts, Ring adopted a blue octagon mark that is virtually indistinguishable from ADT's iconic blue octagon mark, which is protected under numerous federal trademark registrations. ADT's blue octagon is iconic in the security market, proudly displayed on lawn signs and stickers at the homes and businesses of ADT's more than 6.5 million customers across the United States. Following an attempt to imitate ADT's lawn signs, Ring went further and blatantly assimilated ADT's logo into its Ring Alarm Outdoor Siren, according to the complaint. The infringement constitutes Ring's second attempted theft of ADT property. In 2017 Ring obtained an unauthorized copy of a software platform, related trade secrets, and other assets that ADT had spent two years and millions of dollars developing, the complaint explains. ADT brought suit in Delaware and succeeded in enjoining Ring from using the stolen platform before Ring settled with ADT. Now operating as an Amazon company, Ring is again attempting another open theft-this time the theft of ADT's iconic trademark-"seeking to tout a reputation for trust to potential customers that it has not earned," the complaint asserts. Ring believes it can trick consumers who will see a solid blue octagon and believe it is ADT, the most trusted brand in security. As the complaint asserts, "Indeed, even though the blue octagon mark that Ring is using includes the Ring name, ... people will believe that Ring is providing a security service on par with ADT-or, worse, that Ring is providing its security service in partnership with ADT." ADT's suit alleges willful trademark infringement, unfair competition, and false designation of origin under the Lanham Act, 15 U.S.C. SectionSection 1114 and 1125(a); common law trademark infringement; violation of Florida Unfair Competition Law; and Trademark Dilution under the Lanham Act, 15 U.S.C. Section 1125(c) and under Fla. Stat. Section 495.151."

07:06 EDT Rockwell Medical announce marketing approval for Triferic ANU in Canada - Rockwell Medical announced that Triferic AVNU received a Notice of Compliance from Health Canada for the replacement of iron to maintain hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease. Rockwell Medical expects Triferic AVNU to become commercially available in Canada during 2022. "The approval of Triferic AVNU by Health Canada is the first international regulatory approval for our intravenous therapy and marks important progress for our strategy to bring Triferic to markets around the world," said Russell Ellison, M.D., president and CEO of Rockwell Medical. "There are more than 20,000 Canadians undergoing dialysis. We expect Triferic AVNU to be an important new treatment option for dialysis clinics and the patients they serve."

07:02 EDT Ford to build new light commercial vehicle in Romania in 2023 - Ford confirmed that it will invest $300M to build a new light commercial vehicle in 2023 at its Craiova Assembly Plant in Romania, including an all-electric version due to debut in 2024 - the first all-electric Ford volume vehicle to be built in Romania. "Adding an all-electric version in 2024 means Craiova will be our third facility in Europe to build an all-electric vehicle. It follows recent investments this year in the Ford Cologne Electrified Vehicle Center in Germany and Ford Otosan's Kocaeli plant in Turkey and sends another clear signal that we are on an accelerated path to providing our commercial vehicle customers with a zero emissions future in Europe," said Stuart Rowley, president, Ford of Europe.

06:59 EDT Raytheon Technologies reports Q1 backlog $147.4B - Backlog at the end of Q1 was $147.4B, of which $82.2B was from commercial aerospace and $65.2B was from defense.

06:52 EDT Kontoor Brands, Panda Biotech expand collaboration - Kontoor Brands announced an expansion of its collaboration with Dallas-based Panda Biotech, "an emerging leader in the industrial hemp fiber industry." With this collaboration, Kontoor Brands and Panda Biotech are working to bring traceability and scale to the textile-grade cottonized hemp grown and processed in the United States. Through the Panda Biotech collaboration, which first kicked off in 2019 after the passing of the Agriculture Improvement Act of 2018, Kontoor Brands plans to have U.S. grown and processed hemp in market in its denim apparel by 2023.

06:50 EDT BP expects 2021 reported upstream production to be lower than 2020 - The company said, "We now expect disposal proceeds for the year to reach $5-6 billion during the latter stages of 2021. As a result of this quarter's divestments, our target of $25 billion of disposal and other proceeds between the second half of 2020 and 2025 is now underpinned by agreed or completed transactions of around $14.7 billion with approximately $10 billion of proceeds received.bp continues to expect capital expenditure, including inorganic capital expenditur*, of around $13 billion in 2021. Depreciation, depletion and amortization is expected to be at a similar level to 2020. Gulf of Mexico oil spill payments are expected to be around $1 billion post tax.The other businesses & corporate underlying annual charge is expected to be in the range of $1.2-1.4 billion for 2021. The quarterly charges may vary from quarter to quarter. The underlying ETR for 2021 is expected to be higher than 40% but is sensitive to the impact that volatility in the current environment may have on the geographical mix of the group's profits and losses.For full year 2021 we expect reported upstream production to be lower than 2020 due to the impact of the ongoing divestment programme. However, underlying production should be slightly higher than 2020 with the ramp-up of major projects, primarily in gas regions, partly offset by the impacts of reduced capital investment and decline in lower-margin gas assets."

06:48 EDT BP expects Q2 reported upstream production to be lower than Q1 - The company said, "We expect second quarter reported upstream production to be lower than the first quarter mainly due to divestments and seasonal maintenance activities, primarily in the Gulf of Mexico, the North Sea and Trinidad, partly offset by the ramp-up of the Raven and KG D6 R Cluster major projects*. Within this, we expect both gas & low carbon energy and oil production & operations to be lower. -We expect higher product demand across our customer businesses in the second quarter as restrictions begin to ease and vaccination rollouts continue. This should help provide some support to industry refining margins. However, realized refining margins are expected to show a smaller improvement due to the slower recovery in diesel and jet demand and a narrower North American heavy crude oil differential. In addition, we expect a higher level of turnaround activity in our refining portfolio"

06:47 EDT Merck to hold investor briefing featuring Organon on May 3 - Merck announced that members of Organon management will host a virtual investor event where they will present the Organon business strategy, opportunities for growth and financial outlook, followed by a question and answer session on Monday, May 3 at 10:00 am EDT.

06:47 EDT Merck in pact with five Indian generic manufacturers for molnupiravir - Merck announced that the company has entered into non-exclusive voluntary licensing agreements for molnupiravir with five established Indian generics manufacturers. Molnupiravir is an investigational oral antiviral agent currently being studied in a Phase 3 trial for the treatment of non-hospitalized patients with confirmed COVID-19. Merck is developing molnupiravir in collaboration with Ridgeback Biotherapeutics. Merck has entered into these agreements to accelerate availability of molnupiravir in India and in other low- and middle-income countries following approvals or emergency authorization by local regulatory agencies. "The scale of human suffering in India at this moment is devastating, and it is clear that more must be done to help alleviate it. These agreements, toward which we have been working as we have been studying molnupiravir, will help to accelerate access to molnupiravir in India and around the world," said Kenneth C. Frazier, chairman and CEO, Merck. "We remain committed to aiding in the global response that will bring relief to the people of India and, ultimately, bring an end to the pandemic." The agreements have been signed with Cipla Limited, Dr. Reddy's Laboratories Limited, Emcure Pharmaceuticals Limited, Hetero Labs Limited and Sun Pharmaceutical Industries Limited - five generics manufacturers with World Health Organization Pre-Qualified Manufacturing facilities and experience as major suppliers to global and key LMIC procurers. Under the agreements, Merck will provide licenses to these manufacturers to supply molnupiravir to India and more than 100 LMICs. Merck is also in discussions with the Medicines Patent Pool to explore the potential for additional licenses. Separately, Merck will also donate more than $5M worth of oxygen-production equipment, masks, hand sanitizer and financial aid to support relief efforts in India.

06:44 EDT Graphic Packaging announces intent to acquire Americraft Carton for $280M - The company intends to acquire Americraft Carton for approximately $280M. The proposed acquisition is expected to add approximately $200M in sales, $30M in adjusted EBITDA and opportunities for paperboard integration upon completion. Synergies are expected to contribute an additional $10M of adjusted EBITDA within 24 months of closing. The transaction includes seven well-capitalized converting facilities and an outstanding team of dedicated employees.

06:39 EDT GameStop up over 7.5% in pre-market after completing at-the-market offering - Shares of GameStop are up 7.5% in the pre-market at $181.80. Yesterday evening, the company announced that it has "completed its previously announced "at-the-market" equity offering program. GameStop disclosed on April 5, 2021 that it had filed a prospectus supplement with the SEC to offer and sell up to a maximum of 3.5M shares of its common stock from time to time through the ATM Offering. The company ultimately sold 3.5M of common stock and generated aggregate gross proceeds before commissions and offering expenses of approximately $551M. Net proceeds will be used to continue accelerating GameStop's transformation as well as for general corporate purposes and further strengthening the Company's balance sheet."

06:37 EDT Eli Lilly reports Q1 Humulin sales $321.7M, up 2% - The company said, "For the first quarter of 2021, worldwide Humulin revenue increased 2 percent compared with the first quarter of 2020, to $321.7 million. U.S. revenue increased 2 percent, to $219.0 million, driven by higher realized prices, partially offset by decreased demand. Revenue outside the U.S. increased 1 percent, to $102.7 million, primarily due to the favorable impact of foreign exchange rates and higher realized prices, largely offset by decreased volume."

06:35 EDT Eli Lilly reports Q1 Alimta sales $559M - The company said, "For the first quarter of 2021, worldwide Alimta revenue remained flat compared with the first quarter of 2020, at $559.0 million. U.S. revenue decreased 19 percent, to $261.1 million, primarily driven by lower volume as a result of customer buying patterns and, to a lesser extent, lower realized prices. Revenue outside the U.S. increased 26 percent to $297.8 million, primarily driven by increased volume in Germany and, to a lesser extent, the favorable impact of foreign exchange rates. The company expects volume declines in the second half of 2021 for Alimta as a result of the anticipated entry of generic competition due to the loss of patent exclusivity in Japan and major European markets."

06:33 EDT PulteGroup reports Q1 home closings up 12% at 6,044 - The company states: "Net new orders for the first quarter increased 31% from the prior year to 9,852 homes. The dollar value of net new orders in the first quarter was $4.6 billion, which is an increase of 42% over the prior year. The Company operated from an average of 837 communities in the first quarter, which is a decrease of 4% from last year's average of 873 communities."

06:33 EDT Eli Lilly reports Q1 Trulicity sales $1.45B, up 18% - The company said, "First-quarter 2021 worldwide Trulicity revenue was $1.452 billion, an increase of 18 percent compared with the first quarter of 2020. U.S. revenue increased 20 percent, to $1.117 billion, driven by increased demand, partially offset by lower realized prices. Trulicity's lower realized prices in the U.S. were primarily due to higher contracted rebates, partially offset by a favorable segment mix that reflected lower utilization in the 340B segment, and modest list price increases. Revenue outside the U.S. was $335.7 million, an increase of 12 percent, driven by increased volume and, to a lesser extent, favorable foreign exchange rates, partially offset by lower realized prices."

06:28 EDT GE sees $3.5B-$4B Industrial cash use to be adjusted out of Industrial FCF

06:26 EDT General Electric sees aviation recovery beginning in 2H

06:24 EDT General Electric reports Q1 Power revenue $3.92B, Aviation revenue $4.99B - Reports Q1 Renewable Energy revenue $3.25B, Healthcare revenue $4.31B.

06:23 EDT General Electric reports Q1 GE Industrial free cash flow ($0.8B) - GE Industrial CFOA was ($0.5B).

06:19 EDT HSBC sees MSD percentage growth in consumer lending during 2021 - The company said: "Our 1Q21 results were favorably impacted by net ECL releases, particularly in the UK, reflecting improved economic forecasts. There remains a high degree of uncertainty as countries emerge from the pandemic at different speeds and as government support measures unwind. Based on the current consensus economic forecasts trajectory, we expect our ECL charge for 2021 to be below the medium-term range of 30bps to 40bps of average loans that we indicated at our 2020 annual results. We expect mid-single-digit percentage growth in customer lending during 2021. This growth remains highly dependent on the speed at which economies recover from the Covid-19 pandemic, together with the duration of various government support measures and restrictions."

06:17 EDT UPS not providing FY21 earnings, revenue guidance - Given continued economic uncertainty, the company is not providing 2021 revenue or diluted earnings per share guidance; however, it is re-affirming its full-year capital allocation plans.

06:16 EDT Sequans targets 10% sequential increase in revenue for Q2 - The company said, "The following statement is based on management's current assumptions and expectations and assumes no increase in the severity or duration of the COVID-19 pandemic. This statement is forward-looking and actual results may differ materially. Despite the continued supply chain constraints for materials, and factoring in the risk related to the portable router business, management is targeting a 10% sequential increase in revenue."

06:10 EDT Pacific Premier raises quarterly dividend to 33c from 30c per share - Payable on May 14 to stockholders of record as of May 7.

06:01 EDT UPS backs FY21 CapEx view $4B - For FY21: The sale of UPS Freight is expected to close in the second quarter. Capital expenditures are planned to be about $4B. Long-term debt repayments, including $1.5B repaid in the first quarter of 2021, will total $2.5B. Effective tax rate for the remainder of the year is expected to be around 23.5%. The company has no plans to repurchase shares.

05:23 EDT Rio Tinto chief legal officer Barbara Levi to depart in October - Barbara Levi, chief legal officer and external affairs, has accepted a position at UBS (UBS) and will leave Rio Tinto (RIO) by the end of October. A search has commenced to identify a suitable successor. Jakob Stausholm, CEO said, "Barbara has made a significant contribution during her time with Rio Tinto and we will be saddened to see her leave. We offer her our very best wishes for the future."